Say aaah: sore throat cure will be financial true Blis

By Nicholas Bryant

Friday 1st September 2000

COUGH LOLLY: The ground-breaking research is believed to have isolated an anti-bacterial protein that can cure streptococcal throat infections

Investment pied piper Howard Paterson is about to launch a new company which claims to have found the holy grail of health: a cure for the sore throat.

Broking sources said the company, Blis Technology, is within weeks of being quoted on the secondary board of unlisted securities, alongside Mr Patterson's white-hot A2 Corporation.

A2's share price increased 4000% in four months based on reports the company had isolated a milk protein in cows, A1, that increased the incidence of heart disease and diabetes.

The company is hoping to gain exclusive rights to milk products produced by "A2" cows which lack the troublesome protein.

But sources said Blis Technology has the potential to be even bigger than A2 as it is believed to have discovered a cure for an ailment that affects practically everybody - a sore throat.

Blis is an acronym for bacteriocin-like inhibitory substances.

Its exclusive technology, developed by a group of local scientists, focuses on a naturally occurring organism called salivaricin B.

The ground-breaking research is believed to have isolated an anti-bacterial protein that can cure streptococcal throat infections.

The market for strep-throat cures is huge, but most such conditions are receptive to treatment with penicillin-based antibiotics.

Doctors canvassed for their opinion of Blis's potential said it was obviously huge, but little could be ascertained without seeing the science.

"It sounds like quite a breakthrough, more along organic lines than traditional medicine, like the bug that kills the fruitfly in the orchard," one said.

Sources said Blis Technology was actively pursuing commercial possibilities of its discovery and was already negotiating with multinational firms.

International patent applications are also believed to have been lodged.

The prospect is understood to have been so promising among Blis's investors, many of whom also own shares in A2, that its private float was four times oversubscribed.

Comments from our readers

No comments yet